Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wolf, P; Hofer, A; Weger, W; Posch-Fabian, T; Gruber-Wackernagel, A; Legat, FJ.
311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients.
Photodermatol Photoimmunol Photomed. 2011; 27(4):186-189
Doi: 10.1111/j.1600-0781.2011.00594.x
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Wolf Peter
- Co-Autor*innen der Med Uni Graz
- Gruber-Wackernagel Alexandra
- Hofer Angelika
- Legat Franz
- Posch-Fabian Timea
- Weger Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Treatment with the tumor necrosis factor-alpha antibody adalimumab for 12-16 weeks produces a satisfactory response [i.e., 75% reduction in psoriasis area and severity index (PASI)] in a majority (70-80%) of patients with psoriasis. We asked whether 311 nm ultraviolet B (UVB) can improve therapeutic response of psoriatic lesions to adalimumab. Four patients (age range, 49-67 years) with moderate to severe plaque-type psoriasis were treated with standard dosage of adalimumab. During adalimumab therapy, a randomly selected body half (left or right, excluding the head) was irradiated with 311 nm UVB three times weekly for 6 weeks. Treatment response was monitored weekly in terms of half-body PASI. 311 nm UVB significantly accelerated the therapeutic response during adalimumab treatment. At the start of 311 nm UVB therapy, the mean PASI was 14.8. After 6 weeks of 311 nm UVB therapy, the mean PASI was 2.0 on UV-irradiated body halves and 6.9 on non-irradiated body halves (difference, 4.9; 95% confidence interval, 0.4-9.4; P=0.041; 2-tailed paired t-test). This corresponded to an overall mean PASI reduction from baseline (i.e., adalimumab start) of 86% on UV-irradiated body halves vs. 53% on non-irradiated body halves. 311 nm UVB may accelerate and improve the clearance of psoriatic lesions in adalimumab-treated patients. © 2011 John Wiley & Sons A/S.
- Find related publications in this database (using NLM MeSH Indexing)
- Adalimumab -
- Aged -
- Anti-Inflammatory Agents - administration & dosage
- Antibodies, Monoclonal - administration & dosage
- Antibodies, Monoclonal, Humanized -
- Combined Modality Therapy -
- Female -
- Humans -
- Male -
- Middle Aged -
- Psoriasis - therapy
- Remission Induction -
- Ultraviolet Rays -
- Ultraviolet Therapy -
- Find related publications in this database (Keywords)
- adalimumab
- combination therapy
- psoriasis
- ultraviolet
- 311 nm